Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — H1 2021 Earnings Presentation
13 slides from Vita Life Sciences's earnings presentation, Aug 20, 2021
Slide 1: Half Year Financial Results for the 6 Months to 30 June 2021
For personal use only HALF YEAR FINANCIAL RESULTS FOR THE 6 MONTHS TO 30 JUNE 2021 1
Slide 2: Overview, Values and History
OVERVIEW VALUES Vita Life Sciences is a multinational healthcare Vita Life Sciences has a companywide commitment to: For personal use only company involved in the formulation and • Focus its efforts on the health and well-being of customers distribution of high quality vitamins and • Conduct activit
Slide 3: Key Financial Highlights
KEY FINANCIAL HIGHLIGHTS For personal use only • Record first half revenue of $25.7 million, up 17% on prior corresponding period (PCP) reflecting impact of GROUP SALES GROUP EBIT increased channels of distribution A$’m A$’m • Strong brand representation across all major 27 5 E-commerce platforms in
Slide 4: Australia and Malaysia
AUSTRALIA MALAYSIA For personal use only Revenue Up 36% EBIT Up 14% Revenue up 8% EBIT Up 11 % A$’m A$’m A$’m A$’m 14 2.5 9 2.5 13 2 8 2 12 1.5 1.5 11 7 1 1 10 6 9 0.5 0.5 8 0 5 0 HALF YEAR HALF YEAR HALF YEAR HALF YEAR 2021 2020 2021 2020 2021 2020 2021 2020 • Sales of $13.1million, an increase of
Slide 5: Marketing
MARKETING For personal use only Q1 – Magnesium Night Plus Q2 – Immunity with ‘Charli Robinson’ Q1 – Fiit-S Q2 – Turmeric EDM Content Web banner advertising Web banner advertising YouTube Outdoor Billboard Advertsiing Social media images Print advertising Social media images Website articles Social m
Slide 6: Singapore and Other Asia
SINGAPORE OTHER ASIA For personal use only Revenue Up 7% EBIT down 9% Revenue down 30% A$’m A$’m 0.6 2 A$’m 1.5 2.5 0.4 2 1 0.2 1.5 0.5 1 0 0 HALF YEAR HALF YEAR HALF YEAR 2021 2020 2021 2020 2021 2020 • Sales of $2.6 million, an increase of 7% over PCP • Sales of $1.4 million, a decrease of 30% on
Slide 7: Interim Dividend & Cashflows
INTERIM DIVIDEND & CASHFLOWS For personal use only • Gross operating cashflow conversion to Gross operating cashflow Interim fully franked EBITDA continued to exceed 100% to EBITDA dividend • Fully franked interim dividend declared (cents/ share) of 2.75 cents per share for HY21 up 1.25 3 cents per
Slide 8: Outlook
For personal use only OUTLOOK • The success of the Group’s medium-term strategy of increasing channels of distribution is expected to continue with further growth anticipated. • Retail conditions in the Group’s markets are expected to be mixed due to uncertainties arising from Covid-19. • Directors
Slide 9: Half Year 2021 Results
HALF YEAR 2021 RESULTS For personal use only Half year ended June 2021 2020 $’m $’m Revenue 25.7 22.0 EBITDA 5.1 4.5 EBIT 4.9 4.2 Profit before tax 4.9 4.2 Profit after tax 3.7 3.1 EPS (Diluted-cents) 7.02 5.84 Dividend (cents / share) 2.75 1.50 HALF YEAR FINANCIAL RESULTS | FOR THE 6 MONTHS TO 30 J
Slide 10: Balance Sheet
BALANCE SHEET For personal use only Balance Sheet as at June 2021 December 2020 $’m $’m Current assets 30.8 29.2 Non-current assets 9.8 9.9 Total assets 40.6 39.1 Current liabilities 13.4 13.0 Non-current liabilities 0.4 1.7 Total Liabilities 13.8 14.7 Net Assets 26.8 24.4 HALF YEAR FINANCIAL RESULT
Slide 11: Cash Flow
CASH FLOW For personal use only Cash Flow for the half year ended June 2021 2020 $’m $’m Receipts from customers 27.4 25.6 Payments to suppliers and employees (22.1) (20.0) Gross operating cash flow 5.3 5.6 EBITDA 5.1 4.6 Gross operating cash flow / EBITDA 103.9% 121.7% Net interest (paid) (0.0) (0.
Slide 12: Contact
CONTACT For personal use only & +61 2 9545 2633 1/ 102 Bath Road, Kirrawee, NSW 2232 enquiries@vitalifesciences.com.au ANDREW O’KEEFE MANAGING DIRECTOR CHIN L KHOO CHIEF FINANCIAL OFFICER @ vitalifesciences.com.au HALF YEAR FINANCIAL RESULTS | FOR THE 6 MONTHS TO 30 JUNE 2021 12 12
Slide 13: Thank You and Disclaimer
For personal use only THANK YOU DISCLAIMER: This document has been prepared Certain statements in this presentation are or implied) is given or made by Vita Life Sciences Subject to any continuing obligation under by Vita Life Sciences Limited (Vita Life Sciences) and forward looking statements that